145 related articles for article (PubMed ID: 20443891)
1. Identification of biomarkers in human head and neck tumor cell lines that predict for in vitro sensitivity to gefitinib.
Hickinson DM; Marshall GB; Beran GJ; Varella-Garcia M; Mills EA; South MC; Cassidy AM; Acheson KL; McWalter G; McCormack RM; Bunn PA; French T; Graham A; Holloway BR; Hirsch FR; Speake G
Clin Transl Sci; 2009 Jun; 2(3):183-92. PubMed ID: 20443891
[TBL] [Abstract][Full Text] [Related]
2. Signaling via ErbB2 and ErbB3 associates with resistance and epidermal growth factor receptor (EGFR) amplification with sensitivity to EGFR inhibitor gefitinib in head and neck squamous cell carcinoma cells.
Erjala K; Sundvall M; Junttila TT; Zhang N; Savisalo M; Mali P; Kulmala J; Pulkkinen J; Grenman R; Elenius K
Clin Cancer Res; 2006 Jul; 12(13):4103-11. PubMed ID: 16818711
[TBL] [Abstract][Full Text] [Related]
3. Determinants of response to epidermal growth factor receptor tyrosine kinase inhibition in squamous cell carcinoma of the head and neck.
Rogers SJ; Box C; Chambers P; Barbachano Y; Nutting CM; Rhŷs-Evans P; Workman P; Harrington KJ; Eccles SA
J Pathol; 2009 May; 218(1):122-30. PubMed ID: 19197951
[TBL] [Abstract][Full Text] [Related]
4. Preclinical activity of gefitinib in non-keratinizing nasopharyngeal carcinoma cell lines and biomarkers of response.
Ma BB; Lui VW; Poon FF; Wong SC; To KF; Wong E; Chen H; Lo KW; Tao Q; Chan AT; Ng MH; Cheng SH
Invest New Drugs; 2010 Jun; 28(3):326-33. PubMed ID: 19756373
[TBL] [Abstract][Full Text] [Related]
5. Antitumor activity of the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor gefitinib (ZD1839, Iressa) in non-small cell lung cancer cell lines correlates with gene copy number and EGFR mutations but not EGFR protein levels.
Helfrich BA; Raben D; Varella-Garcia M; Gustafson D; Chan DC; Bemis L; Coldren C; Barón A; Zeng C; Franklin WA; Hirsch FR; Gazdar A; Minna J; Bunn PA
Clin Cancer Res; 2006 Dec; 12(23):7117-25. PubMed ID: 17145836
[TBL] [Abstract][Full Text] [Related]
6. Gefitinib (IRESSA) sensitive lung cancer cell lines show phosphorylation of Akt without ligand stimulation.
Noro R; Gemma A; Kosaihira S; Kokubo Y; Chen M; Seike M; Kataoka K; Matsuda K; Okano T; Minegishi Y; Yoshimura A; Kudoh S
BMC Cancer; 2006 Dec; 6():277. PubMed ID: 17150102
[TBL] [Abstract][Full Text] [Related]
7. Involvement of EGFR in the response of squamous cell carcinoma of the head and neck cell lines to gefitinib.
Taguchi T; Tsukuda M; Imagawa-Ishiguro Y; Kato Y; Sano D
Oncol Rep; 2008 Jan; 19(1):65-71. PubMed ID: 18097577
[TBL] [Abstract][Full Text] [Related]
8. Proteomic signatures of epidermal growth factor receptor and survival signal pathways correspond to gefitinib sensitivity in head and neck cancer.
Pernas FG; Allen CT; Winters ME; Yan B; Friedman J; Dabir B; Saigal K; Mundinger GS; Xu X; Morris JC; Calvo KR; Van Waes C; Chen Z
Clin Cancer Res; 2009 Apr; 15(7):2361-72. PubMed ID: 19318490
[TBL] [Abstract][Full Text] [Related]
9. Nuclear translocation of epidermal growth factor receptor by Akt-dependent phosphorylation enhances breast cancer-resistant protein expression in gefitinib-resistant cells.
Huang WC; Chen YJ; Li LY; Wei YL; Hsu SC; Tsai SL; Chiu PC; Huang WP; Wang YN; Chen CH; Chang WC; Chang WC; Chen AJ; Tsai CH; Hung MC
J Biol Chem; 2011 Jun; 286(23):20558-68. PubMed ID: 21487020
[TBL] [Abstract][Full Text] [Related]
10. Gefitinib inhibition of drug resistance to doxorubicin by inactivating ABCG2 in thyroid cancer cell lines.
Lopez JP; Wang-Rodriguez J; Chang C; Chen JS; Pardo FS; Aguilera J; Ongkeko WM
Arch Otolaryngol Head Neck Surg; 2007 Oct; 133(10):1022-7. PubMed ID: 17938326
[TBL] [Abstract][Full Text] [Related]
11. In vitro study of normoxic epidermal growth factor receptor-induced hypoxia-inducible factor-1-alpha, vascular endothelial growth factor, and BNIP3 expression in head and neck squamous cell carcinoma cell lines: Implications for anti-epidermal growth factor receptor therapy.
Secades P; de Santa-María IS; Merlo A; Suarez C; Chiara MD
Head Neck; 2015 Aug; 37(8):1150-62. PubMed ID: 24798801
[TBL] [Abstract][Full Text] [Related]
12. An update of the mechanisms of resistance to EGFR-tyrosine kinase inhibitors in breast cancer: Gefitinib (Iressa) -induced changes in the expression and nucleo-cytoplasmic trafficking of HER-ligands (Review).
Ferrer-Soler L; Vazquez-Martin A; Brunet J; Menendez JA; De Llorens R; Colomer R
Int J Mol Med; 2007 Jul; 20(1):3-10. PubMed ID: 17549382
[TBL] [Abstract][Full Text] [Related]
13. Transforming growth factor alpha expression drives constitutive epidermal growth factor receptor pathway activation and sensitivity to gefitinib (Iressa) in human pancreatic cancer cell lines.
Pino MS; Shrader M; Baker CH; Cognetti F; Xiong HQ; Abbruzzese JL; McConkey DJ
Cancer Res; 2006 Apr; 66(7):3802-12. PubMed ID: 16585207
[TBL] [Abstract][Full Text] [Related]
14. Deregulated cyclin D1 expression is associated with decreased efficacy of the selective epidermal growth factor receptor tyrosine kinase inhibitor gefitinib in head and neck squamous cell carcinoma cell lines.
Kalish LH; Kwong RA; Cole IE; Gallagher RM; Sutherland RL; Musgrove EA
Clin Cancer Res; 2004 Nov; 10(22):7764-74. PubMed ID: 15570011
[TBL] [Abstract][Full Text] [Related]
15. Establishment and characterization of a model of acquired resistance to epidermal growth factor receptor targeting agents in human cancer cells.
Benavente S; Huang S; Armstrong EA; Chi A; Hsu KT; Wheeler DL; Harari PM
Clin Cancer Res; 2009 Mar; 15(5):1585-92. PubMed ID: 19190133
[TBL] [Abstract][Full Text] [Related]
16. HDAC inhibitor vorinostat enhances the antitumor effect of gefitinib in squamous cell carcinoma of head and neck by modulating ErbB receptor expression and reverting EMT.
Bruzzese F; Leone A; Rocco M; Carbone C; Piro G; Caraglia M; Di Gennaro E; Budillon A
J Cell Physiol; 2011 Sep; 226(9):2378-90. PubMed ID: 21660961
[TBL] [Abstract][Full Text] [Related]
17. Chemoresistant tumor cell lines display altered epidermal growth factor receptor and HER3 signaling and enhanced sensitivity to gefitinib.
Servidei T; Riccardi A; Mozzetti S; Ferlini C; Riccardi R
Int J Cancer; 2008 Dec; 123(12):2939-49. PubMed ID: 18803287
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of epidermal growth factor receptor signalling reduces hypercalcaemia induced by human lung squamous-cell carcinoma in athymic mice.
Lorch G; Gilmore JL; Koltz PF; Gonterman RM; Laughner R; Lewis DA; Konger RL; Nadella KS; Toribio RE; Rosol TJ; Foley J
Br J Cancer; 2007 Jul; 97(2):183-93. PubMed ID: 17533397
[TBL] [Abstract][Full Text] [Related]
19. Aberrant expression of cortactin in head and neck squamous cell carcinoma cells is associated with enhanced cell proliferation and resistance to the epidermal growth factor receptor inhibitor gefitinib.
Timpson P; Wilson AS; Lehrbach GM; Sutherland RL; Musgrove EA; Daly RJ
Cancer Res; 2007 Oct; 67(19):9304-14. PubMed ID: 17909038
[TBL] [Abstract][Full Text] [Related]
20. Restoring E-cadherin expression increases sensitivity to epidermal growth factor receptor inhibitors in lung cancer cell lines.
Witta SE; Gemmill RM; Hirsch FR; Coldren CD; Hedman K; Ravdel L; Helfrich B; Dziadziuszko R; Chan DC; Sugita M; Chan Z; Baron A; Franklin W; Drabkin HA; Girard L; Gazdar AF; Minna JD; Bunn PA
Cancer Res; 2006 Jan; 66(2):944-50. PubMed ID: 16424029
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
